共查询到20条相似文献,搜索用时 0 毫秒
1.
Cowan TM Kazerouni NN Dharajiya N Lorey F Roberson M Hodgkinson C Schrijver I 《Molecular genetics and metabolism》2012,106(4):485-487
We report population findings from newborn screening for biotinidase deficiency in California, representing over 2,000,000 newborns. The incidence of profound deficiency was 1/73,629, higher than in other reported populations. Out of 28 patients with profound biotinidase deficiency, 19 were of Hispanic descent, suggesting an increased frequency among this group. Of the 28 patients, 23 underwent mutation analysis of the BTD gene, with one common mutation, 528G>T, found in 43.3% of Hispanic alleles tested. 相似文献
2.
《Genetics in medicine》2017,19(4):396-402
PurposeWe began screening newborns for biotinidase deficiency disorder in 1984, and now all states in the United States and many countries perform this screening. The purpose of this study was to determine the outcomes of older adolescent and adult individuals with the disorder identified by newborn screening.Subjects and methodsWe located and surveyed, by questionnaire and telephone interviews, 44 individuals with profound biotinidase deficiency identified by newborn screening with a mean age of 23.1 years.ResultsAll individuals had successfully completed high school, and many were attending or had completed college or graduate school. Compliance in using biotin has been excellent. Several individuals developed a variety of symptoms when they discontinued biotin for days or weeks. These features readily resolved when biotin was resumed. In addition, five treated women had nine uneventful pregnancies and deliveries.ConclusionsNewborn screening for profound biotinidase deficiency and early treatment with biotin result in excellent outcomes for older adolescents and adults with the disorder. In addition, mothers with profound biotinidase deficiency who were treated with biotin had pregnancies with good outcomes. These outcome results indicate that newborn screening for biotinidase deficiency is one of the most successful newborn screening programs.Genet Med 19 4, 396–402. 相似文献
3.
《Genetics in medicine》2015,17(3):205-209
PurposeBiotinidase deficiency, if untreated, usually results in neurological and cutaneous symptoms. Biotin supplementation markedly improves and likely prevents symptoms in those treated early. All states in the United States and many countries perform newborn screening for biotinidase deficiency. However, there are few studies about the outcomes of the individuals identified by newborn screening.MethodsWe report the outcomes of 142 children with biotinidase deficiency identified by newborn screening in Michigan over a 25-year period and followed in our clinic; 22 had profound deficiency and 120 had partial deficiency.ResultsIndividuals with profound biotinidase and partial deficiency identified by newborn screening were started on biotin therapy soon after birth. With good compliance, these children appeared to have normal physical and cognitive development. Although some children exhibited mild clinical problems, these are unlikely attributable to the disorder. Biotin therapy appears to prevent the development of neurological and cutaneous problems in our population.ConclusionIndividuals with biotinidase deficiency ascertained by newborn screening and treated since birth appeared to exhibit normal physical and cognitive development. If an individual does develop symptoms, after compliance and dosage issues are excluded, then other causes must be considered. 相似文献
4.
《Genetics in medicine》2010,12(7):464-470
Biotinidase deficiency is an autosomal recessively inherited disorder of biotin recycling that is associated with neurologic and cutaneous consequences if untreated. Fortunately, the clinical features of the disorder can be ameliorated or prevented by administering pharmacological doses of the vitamin biotin. Newborn screening and confirmatory diagnosis of biotinidase deficiency encompasses both enzymatic and molecular testing approaches. These guidelines were developed to define and standardize laboratory procedures for enzymatic biotinidase testing, to delineate situations for which follow-up molecular testing is warranted, and to characterize variables that can influence test performance and interpretation of results. 相似文献
5.
Clinical findings in four children with biotinidase deficiency detected through a statewide neonatal screening program 总被引:4,自引:0,他引:4
B Wolf G S Heard L G Jefferson V K Proud W E Nance K A Weissbecker 《The New England journal of medicine》1985,313(1):16-19
Four children with biotinidase deficiency were identified during the first year of a neonatal screening program for this disease in the Commonwealth of Virginia. Two unrelated probands were identified among the 81,243 newborn infants who were screened. In addition, two siblings of one of these infants were found to be affected. Both probands had mild neurologic symptoms at two and four months, respectively, and the two older children had more severe neurologic abnormalities, cutaneous findings, and developmental delay at two and three years of age. However, none of the affected children had acute metabolic decompensation. Previous studies have shown that the administration of biotin to affected children can be a lifesaving procedure that can reverse acute symptoms and prevent irreversible neurologic damage. Our findings demonstrate that subtle neurologic abnormalities may appear as early as at two months of age and that developmental abnormalities may occur even in the absence of episodes of overt metabolic decompensation. Since screening and treatment are both inexpensive and effective and the incidence of the disease is well within the range of that of other metabolic diseases for which screening is performed, biotinidase deficiency should be added to the group of metabolic diseases for which screening is done in the neonatal period. 相似文献
6.
Molecular characterisation of 34 patients with biotinidase deficiency ascertained by newborn screening and family investigation 总被引:3,自引:0,他引:3
Mühl A Möslinger D Item CB Stöckler-Ipsiroglu S 《European journal of human genetics : EJHG》2001,9(4):237-243
This study characterises the spectrum of biotinidase mutations in 21 patients (17 families) with profound biotinidase deficiency (BD) and 13 unrelated patients with partial BD using a denaturing gradient gel electrophoretic mutation screening and selective sequencing approach. In 29 from 30 unrelated families we found biallelic mutations including four common mutations, D444H (frequency 23.3%), G98:d7i3(20.0%), Q456H(20.0%), T532M (15.0%) and nine rare mutations (V62M, R157H, A171T+D444H, C423W, D543H, L279W, N172S, V109G, 12236G-A) with frequencies less than 5.0%. Only three profound BD patients with G98:d7i3/G98:d7i3 and Q456H/Q456H genotypes and residual biotinidase activities of 0.0%, and 0.9% of normal activity developed clinical symptoms before biotin supplementation at 8 weeks of age. All other patients remained asymptomatic within the first months of life or even longer without treatment. Two patients homozygous for the frameshift mutation G98:d7i3 had no measurable residual enzyme activity. Twelve patients with partial BD had the D444H mutation in at least one allele. We conclude that, based on mutation analysis and biochemical examinations of the enzyme, it is currently not clearly predictable whether an untreated patient will develop symptoms or not, although it seems that patients with activities lower than 1% are at a high risk for developing symptoms of the disease early in life. 相似文献
7.
8.
9.
Karen J. Norrgard Robert J. Pomponio Katie L. Swango Jeanne Hymes Thomas Reynolds Gregory A. Buck Barry Wolf 《Human mutation》1998,11(5):410-410
Biotinidase deficiency is inherited as an autosomal recessive trait that, unless treated with pharmacologic doses of biotin, can result in neurologic and cutaneous symptoms. We have identified two new mutations in exon D of the biotinidase gene of children with profound biotinidase deficiency ascertained by newborn screening. Transition 511G→A near the 5′ end of exon D results in a substitution of threonine for alanine171 (A171T) and transversion 1330G→C occurs close to the 3′ end of exon D causing a substitution of histidine for aspartic acid 444 (D444H). The D444H mutation was detected in four individuals from our normal population whose mean serum biotinidase activity is 5.25 nmol/min/ml, which is significantly lower than the mean normal activity (7.1 nmol/min/ml). We calculated that this mutation causes a 52% loss of activity in the aberrant enzyme. Twenty-three individuals with the D444H mutation were found by allele specific oligonucleotide analysis of DNA from 296 randomly-selected, anonymous dried-blood spots. We estimate the frequency of this allele in the general population to be 0.039. In contrast, no individuals in 376 have the A171T mutation. Fourteen children (eleven probands and three siblings) out of 31 enzyme-deficient children have both the A171T and D444H mutations. Both mutations are inherited from a single parent as a double mutation allele. The nine families in which this allele was identified are of mostly European ancestry, although the mutation cannot be attributed to a specific nationality or ethnic group. The serum of a child who is homozygous for the double mutation allele has very little CRM and the aberrant enzyme has very low biotinyl-hydrolase activity and no biotinyl-transferase activity. This double mutation allele (A171T and D444H) is a common cause of profound biotinidase deficiency in children ascertained by newborn screening in the United States. Hum Mutat 11:410, 1998. © 1998 Wiley-Liss, Inc. 相似文献
10.
John P. Atkinson Karen McGinnis Donald Shreffler 《Journal of immunological methods》1980,33(4):351-368
The previously described one-step hemolytic assay for the fourth component of complement (C4) that employs C4-deficient (C4D) guinea pig serum was modified to allow assessment of mouse C4. Of a number of variables evaluated including the class and quantity of sensitizing antibody, concentration of C4D serum and metals, ionic strength of the buffer, and the duration and temperature of incubation, substitution of IgG anti-sheep red blood cell antibodies for the standard IgM hemolysin and the use of C4D serum at relatively high concentrations (1 : 20) were necessary to obtain an accurate, reproducible and sensitive hemolytic assay. The sensitivity of the assay could be increased approximately 2-fold by the addition of human C2 and approximately 30% by employing 51Cr-labeled sheep red blood cells. The former probably helped to overcome a partial incompatibility between mouse C4 and guinea pig C2 and the latter permitted the use of 10-fold fewer erythrocytes in the assay system. Employing this assay, C4 activity was determined in H2-congenics and recombinants and the effect of age, sex, and methods of procuring and preserving mouse serum and plasma evaluated. In most strains, males had a 10–30% higher level of C4 hemolytic activity than females, and young (<6 weeks) and older (>20 weeks) mice had lower activity compared to mice between 6 and 12 weeks. Procuring samples in 5 mM EDTA (final concentration) and subsequent storage at ?70°C permitted long-term preservation without loss of hemolytic activity. Allowing mouse blood to clot at 4, 22 or 37°C, even for brief periods, was associated with complement activation and depletion of C4 functional activity. C4 assays of H2-congenics and infromative recombinants conclusively demonstrated that this hemolytic activity mapped to the S region of the H-2 complex. 相似文献
11.
K McCormick R M Viscardi B Robinson J Heininger 《American journal of medical genetics》1985,22(2):291-299
We describe the successful use of sodium benzoate in a neonate with hyperammonemia associated with congenital lactic acidosis caused by a partial deficiency of the E1 component of pyruvate dehydrogenase (PDH); of note, this biochemical disturbance has not been previously described in PDH deficiency. The pyruvate dehydrogenase complex in skin fibroblasts had 48% of normal activity with a deficiency of the E1 component. The infant presented with rapid onset of a severe metabolic lactic acidosis, hyperventilation, hyperammonemia, and coma. At 30 hours of age continuous peritoneal dialysis was started; however, plasma NH3 concentrations remained in the 300-400 micrograms/dl range over the next 12 hours. Sodium benzoate, 250 mg/kg, was infused intravenously with a decrease in plasma ammonia of 25 micrograms/dl/hr. Hippurate was documented in the urine and peritoneal fluid after benzoate therapy. At 10.5 months of age, 50 mg/kg dichloroacetate was administered orally under fasting conditions, which resulted in a 56 and 62% reduction in the serum lactate and pyruvate levels, respectively; after 2 weeks on dichloroacetate his fasting levels were significantly decreased. Fibroblast PDH activity responded similarly to this drug. In our patient sodium benzoate was rapidly effective in producing a decline in plasma ammonia that was associated with clinical improvement. We feel that its use in organic acidemias deserves further evaluation and, furthermore, that any child with suspected PDH deficiency requires a clinical trial of dichloroacetate. 相似文献
12.
Thodi G Molou E Georgiou V Loukas YL Dotsikas Y Biti S Papadopoulos K Konstantinou D Antoniadi M Doulgerakis E 《Journal of human genetics》2011,56(12):861-865
Late-onset multiple carboxylase deficiency, also known as biotinidase (BTD) deficiency, is an autosomal recessively inherited disorder of biotin metabolism. Its early diagnosis and treatment seems that it can even fully prevent its various clinical manifestations. Mutations in the BTD gene scattered throughout its coding region have been detected in patients ascertained either through newborn screening or clinically. From March 2010 up to June 2011, 18?954 Greek neonates were subjected to biochemical determination of BTD activity through a semiquantitative fluoroimmunoassay. Subsequently, the first cohort of our 'suspected' samples was further tested for the presence of aberrations associated either with partial or profound BTD deficiency through sequencing of the coding region of the BTD gene, including splice-site junctions. On the basis of the molecular data derived from the study of our first cohort of 'suspected' samples, a panel of four mutations, most frequently encountered in the Greek population, was created, and a rapid, reliable and cost-effective real-time-based genotyping assay for the detection of these mutations was developed. This is the first report about the BTD mutational spectrum in Greece, and it could be a beneficial utility in the differential clinical diagnosis of BTD deficiency. 相似文献
13.
Biotinidase deficiency is an autosomal recessive disorder of biotin metabolism caused by defects in the biotinidase gene. Symptoms of biotinidase deficiency are resolved or prevented with oral biotin supplementation and as such newborn screening is performed to prospectively identify affected individuals prior to the onset of symptoms. Biotinidase deficiency is detected by determining the activity of the biotinidase enzyme utilizing the newborn dried blood spot and colorimetric end point analysis. While newborn screening by enzyme analysis is effective, external factors may compromise results of the enzyme analysis and difficulty is encountered in distinguishing between complete and partial enzyme deficiencies. In the United States, the four mutations most commonly associated with complete biotinidase deficiency are c98:d7i3, Q456H, R538C, and the double mutation D444H:A171T. Partial biotinidase deficiency is almost universally attributed to the D444H mutation. To more effectively distinguish between profound and partial biotinidase deficiency, a panel of assays utilizing real time PCR and melting curve analysis using Light Cycler technology was developed. Employing DNA extracted from the original dried blood specimens from newborns identified through prospective newborn screening as presumptive positive for biotinidase deficiency, the specimens were analyzed for the presence of the five common mutations. Using this approach it was possible to separate newborns with partial and complete deficiency from each other as well as from many of those with false positive results. In most cases it was also possible to correlate the genotype with the degree of residual enzyme activity present. In newborn screening for biotinidase deficiency, we have shown that the analysis of common mutations is useful in distinguishing between partial and complete enzyme deficiency as well as improving specificity. Combining biotinidase enzyme analysis with genotypic data also increases the sensitivity of screening for biotinidase deficiency and provides information useful to clinicians earlier than would otherwise be possible. 相似文献
14.
Erythrocyte pyruvate kinase deficiency was detected in a Cuban girl with congenital nonspherocytic haemolytic anemia. Kinetic and immunochemical studies showed that the case was different from those hitherto reported. The variant(s) was tentatively designated PK "Alquizar", following the recommendations of the International Committee for Standardization in Hematology. 相似文献
15.
16.
17.
Deletion/insertion mutation that causes biotinidase deficiency may result from the formation of a quasipalindromic structure 总被引:2,自引:0,他引:2
Pomponio RJ; Narasimhan V; Reynolds TR; Buck GA; Povirk LF; Wolf B 《Human molecular genetics》1996,5(10):1657-1661
Biotinidase is responsible for recycling the vitamin biotin from biocytin
that is formed after the proteolytic degradation of the biotin- dependent
carboxylases. We have identified a deletion/insertion mutation within exon
D of the human biotinidase gene in a child with biotinidase deficiency. The
mutation causes a frame shift and premature termination which are predicted
to result in a truncated protein. We propose that the mutation occurred
during DNA replication by either of two mechanisms. Both mechanisms involve
formation of a quasipalindromic hairpin loop in the template and
dissociation of DNA polymerase alpha. This mutation supports the formation
of palindromic structures as a possible cause of deletions in eukaryotes,
and supports the proposal, derived from in vitro studies, that polymerase
alpha may preferentially arrest or dissociate at specific template
sequences.
相似文献
18.
Correa-Cerro LS Wassif CA Kratz L Miller GF Munasinghe JP Grinberg A Fliesler SJ Porter FD 《Human molecular genetics》2006,15(6):839-851
Smith-Lemli-Opitz syndrome (SLOS) is a genetic syndrome caused by mutations in the 3beta-hydroxysterol Delta(7)-reductase gene (DHCR7). SLOS patients have decreased cholesterol and increased 7-dehydrocholesterol (7-DHC) levels. Dietary cholesterol supplementation improves systemic biochemical abnormalities; however, because of the blood-brain barrier, the central nervous system (CNS) is not treated. Simvastatin therapy has been proposed as a means to treat the CNS. Mice homozygous for a null disruption of Dhcr7, Dhcr7(Delta3-5/Delta3-5), die soon after birth, thus they cannot be used to study postnatal development or therapy. To circumvent this problem, we produced a hypomorphic SLOS mouse model by introducing a mutation corresponding to DHCR7(T93M). Both Dhcr7(T93M/T93M) and Dhcr7(Delta3-5/T93M) mice are viable. Phenotypic findings in Dhcr7(T93M/Delta3-5) mice include CNS ventricular dilatation and two to three syndactyly. Biochemically, both Dhcr7(T93M/T93M) and Dhcr7(T93M/Delta3-5) mice have elevated tissue 7-DHC levels; however, the biochemical defect improved with age. This has not been observed in human patients, and is due to elevated Dhcr7 expression in mouse tissues. Dietary cholesterol therapy improved sterol profiles in peripheral, but not CNS tissues. However, treatment of Dhcr7(T93M/Delta3-5) mice with simvastatin decreased 7-DHC levels in both peripheral and brain tissues. Expression of Dhcr7 increased in Dhcr7(T93M/Delta3-5) tissues after simvastatin therapy, consistent with the hypothesis that simvastatin therapy improves the biochemical phenotype by increasing the expression of a Dhcr7 allele with residual enzymatic activity. We conclude that simvastatin treatment is efficacious in improving the SLOS-associated sterol abnormality found in the brain, and thus has the potential to be an effective therapeutic intervention for behavioral and learning problems associated with SLOS. 相似文献
19.
The ß1 integrin subfamily, alternatively called verylate activation antigen (VLA), has been implicated in variouscellular functions. In this study, we generated a mAb againstthe mouse ß1 subunit (CD29) to examine the functionalproperty of mouse VLA proteins. After immunization with affinity-purifiedmouse VLA-4 (4ß1), a hamster mAb, HMß1-1,was established by screening mAb that reacted with 4-negatlveneuroblastoma C1300. The antigen defined by HMß1-1was widely distributed in various mouse cell lines and HMß1-1immunoprecipitated a 110-120 kDa protein common to VLA-1 andVLA-6, indicating that HMß1-1 recognizes the ß1subunit of mouse integrins. We then examined the inhibitoryeffect of HMß1-1 on VLA-dependent cell adhesion andactivation. HMß1-1 blocked the adhesion of mouse tumorcell lines to extracellular matrix proteins including collagen,laminin and fibronectin. Moreover, splenic T cell proliferationinduced by anti-CD3 mAb and allogeneic mixed lymphocyte responsewere strongly inhibited by HMß1-1 in combination withan anti-LFA-1 mAb. We conclude that HMß1-1 reactivewith mouse CD29 can inhibit VLA-dependent cellular functionsand, thus, would be useful for studying the physiological roleof ß1 integrins in vivo. 相似文献
20.
Joyce W Yu Gary Pekeles Laurent Legault Christine T McCusker 《Annals of allergy, asthma & immunology》2006,96(4):615-619
BACKGROUND: Cow's milk allergy is one of the most common allergies in infancy. It has an excellent prognosis since most cases resolve by 4 years of age. The complications associated with milk allergy include delayed growth and atopic conditions, such as asthma, allergic rhinitis, atopic dermatitis, and other food allergies. OBJECTIVE: To report a case of vitamin D deficiency rickets in a 2-year-old boy with cow's milk allergy. METHODS: We describe a patient with clinical and biochemical evidence of rickets, including decreased serum calcium, phosphate, and 25-hydroxy vitamin D levels and an elevated alkaline phosphatase level. A dietary history revealed the prolonged absence of dietary vitamin D because the child did not tolerate cow's milk. Skin prick testing and measurement of specific IgE to cow's milk were performed to determine whether there was an allergy to cow's milk. RESULTS: Results of skin prick testing and measurement of specific IgE to cow's milk confirmed an IgE-mediated sensitivity to cow's milk. Introduction of appropriate supplementation into the child's diet resulted in complete resolution of his symptoms. CONCLUSIONS: This case emphasizes that the management of cow's milk allergy involves strict avoidance of the allergenic food while also ensuring that essential dietary requirements are met. A dietary history is crucial at all pediatric visits, and inquiry about supplementation of vitamins and minerals is important, especially in children with food allergies. 相似文献